Search
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalAn irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine). … A propylamine formed from the cyclization of the side chain of amphetamine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSulconazole
go.drugbank.com/drugs/DB06820ApprovedSulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)
Flutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalFlutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density. … It is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029]
Categories: Compounds used in a research, industrial, or household settingCefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnIt is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. It is no longer marketed in the United States.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.[A39048]
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigational[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. … Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.
Almitrine
go.drugbank.com/drugs/DB01430ApprovedAlmitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. … It is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep.
Categories: Compounds used in a research, industrial, or household settingFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigational[A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090] … Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.